Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Conditions

Gemcitabine — DRUG
1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Erlotinib — DRUG
150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Sorafenib — DRUG
400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.

This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.

Experimental: Combination GES
Combination of Gemcitabine, Erlotinib, and Sorafenib

4-month Progression Free Survival (PFS) Rate [ Time Frame: 4 months ]

Facility	City	State	ZIP	Site coordinators
Desert Regional Medical Center	Palm Springs	California	92262	-
Bellevue Hospital	New York	New York	10016	-
New York University Cancer Center	New York	New York	10016	-

By condition

By specialty

By research site